



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria. Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO	
10/050,102	01/18/2002	Norman G. Anderson	2315-150	9065	
7590 08/23/2004			EXAMINER		
John E. Tarcza			LU, FRANK WEI MIN		
Large Scale Biology Corporation 3333 Vaca Valley Parkway			ART UNIT	PAPER NUMBER	
Suite 1000			1634		
Vacaville, CA	95688	DATE MAILED: 08/23/2004			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application	n No.	Applicant(s)		
Office Action Summary		10/050,10	2	ANDERSON ET AL.		
		Examiner		Art Unit		
		Frank W I	_u	1634		
The N	MAILING DATE of this commu y	nication appears on the	cover sheet with th	e correspondence address		
THE MAILIN  - Extensions of t after SIX (6) M  - If the period for - If NO period for - Failure to reply - Any reply recei	MED STATUTORY PERIOD F G DATE OF THIS COMMUN ime may be available under the provision ONTHS from the mailing date of this come reply specified above is less than thirty ( reply is specified above, the maximum is within the set or extended period for reply ved by the Office later than three months erm adjustment. See 37 CFR 1.704(b).	IICATION. s of 37 CFR 1.136(a). In no eve munication. 30) days, a reply within the statu tatutory period will apply and will y will, by statute, cause the apply	ent, however, may a reply b story minimum of thirty (30) Il expire SIX (6) MONTHS f ication to become ABANDO	e timely filed  days will be considered timely. from the mailing date of this communication.  DNED (35 U.S.C. § 133).		
1)☐ Resp	onsive to communication(s) f	iled on				
2a)☐ This	action is <b>FINAL</b> .	2b) This action is	non-final.			
	d in accordance with the prac			, prosecution as to the merits is 1, 453 O.G. 213.		
4)⊠ Claim(s) <u>52,53 and 57-61</u> is/are pending in the application.						
4a) Of	the above claim(s) is/a	are withdrawn from co	nsideration.			
5)☐ Claim	(s) is/are allowed.					
6)⊠ Claim(s) <u>52,53 and 57-61</u> is/are rejected.						
7) Claim	(s) is/are objected to.					
8) Claime	(s) are subject to restri	iction and/or election r	equirement.			
Application Pa	pers					
9)∐ The sp	ecification is objected to by th	ne Examiner.				
10)⊠ The dra	awing(s) filed on 1/10/2002 (c	<u>original)</u> is/are: a)⊠ ad	cepted or b) object	eted to by the Examiner.		
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
11) The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved by the Examiner.						
If approved, corrected drawings are required in reply to this Office action.						
12) <u></u> The oa	th or declaration is objected t	o by the Examiner.				
Priority under 3	35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).						
a)∐ All	b) ☐ Some * c) ☐ None of:					
1.	Certified copies of the priority	y documents have bee	n received.			
2.	Certified copies of the priority	y documents have bee	n received in Appli	cation No		
<del></del>	Copies of the certified copies application from the Inter attached detailed Office acti	national Bureau (PCT	Rule 17.2(a)).			
14)⊠ Acknow	ledgment is made of a claim	for domestic priority u	nder 35 U.S.C. § 11	19(e) (to a provisional application).		
, —	ne translation of the foreign la vledgment is made of a claim					
Attachment(s)		, ,				
2) Notice of Draf	erences Cited (PTO-892) ftsperson's Patent Drawing Review ( isclosure Statement(s) (PTO-1449)			mary (PTO-413) Paper No(s) mal Patent Application (PTO-152)		

Application/Control Number: 10/050,102 Page 2

Art Unit: 1634

#### **DETAILED ACTION**

#### Reopening of Prosecution

1. Based on the Notice of Withdrawal from Issue mailed on November 20, 2003, the examiner reopens prosecution for this case. The claims pending in this application are claims 52, 53, and 57-61.

## Claim Objections

- 2. Claim 53 is objected to because of the following informality: "which could not have been detected if the band were in the upper region by the same detection technique" should be "which can not have been detected if the band is in the upper region by the same detection technique".
- 3. Claim 60 is objected to because of the following informality: "no diffusion between each before centrifugation" should be "no diffusion between said two different fluids before centrifugation".
- 4. Claim 61 is objected to because of the following informality: "an air bubble" should be "the air bubble".

Appropriate correction is required.

### Claim Rejections - 35 USC § 112

5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Art Unit: 1634

6. Claim 53 is rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant is referred to the interim guidelines on written description published on December 21, 1999 in the Federal Register at Volume 64, Number 244, pp.71427-71440.

Vas-Cath Inc. v. Mahurkar, 19USPQ2d 1111 (Fed. Cir. 1991), clearly states that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." Vas-Cath Inc. v. Mahurkar, 19USPQ2d at 1117. The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed". Vas-Cath Inc. v. Mahurkar, 19USPQ2d at 1116.

Although the claim 53 describes detecting a band of particle in the lower region by a detection technique which can not have been detected if the band is in the upper region by the same detection technique, the specification does not provides adequate written descriptions to show what kind of detection techniques can be used to detect a band of particle in the lower region wherein the detection techniques can not be used if the band is in the upper region. The claimed inventions as a whole are not adequately described if the claims require essential or critical elements which are not adequately described in the specification and which are not conventional in the art as of Applicants effective filing date. Possession may be shown by actual reduction to practice, clear depiction of the invention in a detailed drawing, or by describing the

Art Unit: 1634

invention with sufficient relevant identifying characteristics (as it relates to the claimed inventions as a whole) such that a person skilled in the art would recognize that the inventor had possession of the claimed invention. *Pfaff v. Wells Electronics, Inc.*, 48 USPQ2d 1641, 1646 (1998). The general knowledge and level of skill in the art do not supplement the omitted description because specific, not general, guidance is what is needed.

With limited disclosure provided by the specification, the skilled artisan cannot envision a detection technique recited in claim 53 and therefore conception is not achieved until reduction to practice has occurred, regardless of the complexity or simplicity of the method used.

Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method of identifying it. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (Fed. Cir. 1993) and *Amgen Inc. v. Chugai Pharmaceutical Co.* Ltd., 18 USPQ2d 1016 (Fed. Cir. 1991).

One cannot describe what one has not conceived. See *Fiddes v. Baird*, 30 USPQ2d 1481, 1483. In *Fiddes*, claims directed to mammalian FGF's were found to be unpatentable due to lack of written description for that broad class. The specification provided only the bovine sequence. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 U.S.C. §112 is severable from its enablement provision (see page 1115).

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Page 5

Application/Control Number: 10/050,102

Art Unit: 1634

- 8. Claims 52, 53, and 57-61 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.
- 9. Claim 52 is rejected as vague and indefinite because it is unclear whether the phrase "wherein said upper region is separated from said lower region by said middle region having 1) a decreasing diameter from said upper region toward said lower region, 2) a diameter less than said upper region but greater than said lower region, or 3) a diameter equal to said lower region" is a Markush type of language or not since there is no "and" between "1) a decreasing diameter from said upper region toward said lower region" and "2) a diameter less than said upper region but greater than said lower region". Please clarify.
- 10. Claim 61 is rejected as vague and indefinite because it is unclear that an air bubble is in the wall of the centrifuge tube or is in the solution of the centrifuge tube. Please clarify.

#### Claim Rejections - 35 USC § 102

11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent of (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.
- 12. Claims 52 and 57-60 are rejected under 35 U.S.C. 102(e) as being anticipated by Vlasselaer (US Patent NO. 5,663,051, filed on December 11, 1995).

Art Unit: 1634

Vlasselaer teaches separation apparatus and method.

Regarding claims 52, 53, and 57-60, Vlasselaer teaches a centrifuge tube comprising an upper region, a middle region and a lower region wherein an inner diameter of said upper region is larger than an inner diameter of said lower region, wherein said upper region is separated from said lower region by said middle region having a decreasing diameter from said upper region toward said lower region or having a diameter less than said upper region but greater than said lower region as recited in claim 52 (see Figures 1A-1C and 2A-2B). Since Vlasselaer teaches that the fluid sample 18 such as human cells (see examples 1 and 2 in columns 35-38) to be separated is layered on the top of density gradient solution 16 such as CsCl (see column 13, second paragraph) inside the tube so that at least about 1 mm of density gradient solution remains between the sample and the top of the constriction member after layering (see column 8, fourth and fifth paragraphs), Vlasselaer disclose that the sample is a biological sample as recited in claim 57 wherein at least two different fluids (ie., the sample and density gradient solution) are present, each in different region as recited in claim 59 and wherein said two different fluids are held separately with substantially no diffusion between said two different fluids before centrifugation as recited in claim 60. Since Vlasselaer teaches that the tube and its contents are then subjected to centrifugation at a centrifugal force and duration to pellet cells having densities greater than the density of the gradient solution (see column 8, fourth and fifth paragraphs), Vlasselaer discloses centrifuging said sample in said tube to concentrate said particles (ie., the cells) as recited in claim 52. Although Vlasselaer does not teach that said lower region has a sufficiently small bore to hold an air bubble in it with an aqueous solution above and below it, this limitation is a functional limitation of the centrifuge tube taught by Vlasselaer. Since there

Art Unit: 1634

is no structural difference between the centrifuge tube recited in claim 52 and the centrifuge tube taught by Vlasselaer, the centrifuge tube taught by Vlasselaer must have the same function as the centrifuge tube recited in claim 52 so that lower region of the centrifuge tube taught by Vlasselaer has a sufficiently small bore to hold an air bubble in it with an aqueous solution above and below it.

Therefore, Vlasselaer teaches all limitations recited in claims 52 and 57-60.

#### Claim Rejections - 35 USC § 103

- 13. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:
  - (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.
- 14. Claim 58 is rejected under 35 U.S.C. 103(a) as being unpatentable over Vlasselaer (1995) as applied to claims 52 and 57-60 above, and further in view of Mason *et al.*, (US Patent NO. 5,612,040, filed on April 1995).

The teachings of Vlasselaer have been summarized previously, supra.

Vlasselaer does not disclose that the particles are microorganisms as viruses.

Mason *et al.*, teach that microorganisms as viruses are purified by centrifugation (see example 1, columns 6 and 7).

Therefore, it would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to have performed the method recited in claim 57 wherein the particle are microorganisms as viruses in view of the patents of Vlasselaer and Mason *et al.*.

Art Unit: 1634

One having ordinary skill in the art would have been motivated to do so because Mason et al., have successfully purified viruses by centrifugation and the simple replacement of one kind of sample (i.e., human cells taught by Vlasselaer) from another kind of sample (i.e., microorganisms taught by Mason et al.,) during the process for performing the method recited in claim 58 would have been, in the absence of convincing evidence to the contrary, prima facie obvious to one having ordinary skill in the art at the time the invention was made.

Furthermore, the motivation to make the substitution cited above arises from the expectation that the prior art elements will perform their expected functions to achieve their expected results when combined for their common known purpose. Support for making the obviousness rejection comes from the M.P.E.P. at 2144.07 and 2144.09.

Art Unit: 1634

Also note that there is no invention involved in combining old elements is such a manner that these elements perform in combination the same function as set forth in the prior art without giving unobvious or unexpected results. *In re Rose* 220 F.2d. 459, 105 USPQ 237 (CCPA 1955.

#### Conclusion

- 15. No claim is allowed.
- 16. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993)(See 37 CAR § 1.6(d)). The CM Fax Center number is either (703) 872-9306.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Frank Lu, Ph.D., whose telephone number is (571)272-0746. The examiner can normally be reached on Monday-Friday from 9 A.M. to 5 P.M.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion, can be reached on (571)272-0782.

Any inquiry of a general nature or relating to the status of this application should be directed to the Chemical Matrix receptionist whose telephone number is (703) 308-0196.

Frank Lu

PSA

August 17, 2004

POANKIII

PATENT EXAMINER